Cetera Investment Advisers Has $1.41 Million Position in Autolus Therapeutics PLC Sponsored ADR $AUTL

Cetera Investment Advisers raised its position in Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) by 17.6% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 617,172 shares of the company’s stock after purchasing an additional 92,300 shares during the period. Cetera Investment Advisers owned approximately 0.23% of Autolus Therapeutics worth $1,407,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in AUTL. R Squared Ltd acquired a new position in shares of Autolus Therapeutics in the 2nd quarter valued at $50,000. Delaney Dennis R bought a new position in Autolus Therapeutics during the second quarter worth about $55,000. Forefront Wealth Management Inc. acquired a new position in Autolus Therapeutics in the second quarter valued at about $61,000. Vanguard Personalized Indexing Management LLC increased its holdings in shares of Autolus Therapeutics by 63.5% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 30,432 shares of the company’s stock worth $69,000 after acquiring an additional 11,821 shares in the last quarter. Finally, Invesco Ltd. raised its position in shares of Autolus Therapeutics by 53.3% during the first quarter. Invesco Ltd. now owns 32,738 shares of the company’s stock worth $51,000 after purchasing an additional 11,381 shares during the period. 72.83% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts recently issued reports on AUTL shares. William Blair reiterated an “outperform” rating on shares of Autolus Therapeutics in a research report on Wednesday, September 24th. Needham & Company LLC reiterated a “buy” rating and issued a $10.00 price target on shares of Autolus Therapeutics in a report on Monday, November 3rd. Wall Street Zen downgraded shares of Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Saturday, November 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Autolus Therapeutics in a report on Wednesday, October 8th. Finally, Wells Fargo & Company reduced their target price on shares of Autolus Therapeutics from $6.00 to $5.00 and set an “overweight” rating for the company in a research note on Wednesday, August 13th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Autolus Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $8.33.

Autolus Therapeutics Stock Down 2.1%

Shares of AUTL stock opened at $1.38 on Tuesday. Autolus Therapeutics PLC Sponsored ADR has a 12 month low of $1.11 and a 12 month high of $3.45. The company’s fifty day simple moving average is $1.49 and its 200-day simple moving average is $1.81. The firm has a market cap of $367.27 million, a PE ratio of -1.66 and a beta of 2.01.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.07). Autolus Therapeutics had a negative net margin of 439.69% and a negative return on equity of 63.76%. The business had revenue of $21.19 million during the quarter, compared to analyst estimates of $21.08 million. On average, equities analysts predict that Autolus Therapeutics PLC Sponsored ADR will post -0.94 earnings per share for the current fiscal year.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.